Q2 Earnings Forecast for Longeveron Issued By Zacks Research

Longeveron Inc. (NASDAQ:LGVN) – Analysts at Zacks Research raised their Q2 2026 earnings estimates for Longeveron in a report released on Thursday, May 14th. Zacks Research analyst B. Sorensen now anticipates that the company will earn ($0.18) per share for the quarter, up from their prior forecast of ($0.22). The consensus estimate for Longeveron’s current full-year earnings is ($0.70) per share. Zacks Research also issued estimates for Longeveron’s Q3 2026 earnings at ($0.16) EPS, Q4 2026 earnings at ($0.16) EPS, FY2026 earnings at ($0.69) EPS, FY2027 earnings at ($0.71) EPS and FY2028 earnings at ($0.68) EPS.

A number of other research firms have also weighed in on LGVN. Wall Street Zen lowered shares of Longeveron from a “hold” rating to a “sell” rating in a research note on Saturday, May 2nd. HC Wainwright dropped their price target on shares of Longeveron from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Monday, May 4th. Maxim Group lowered shares of Longeveron from a “buy” rating to a “hold” rating in a research report on Monday, May 11th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Longeveron in a research report on Tuesday, April 21st. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $5.50.

Longeveron Stock Up 0.8%

NASDAQ:LGVN opened at $0.68 on Tuesday. The firm has a market capitalization of $15.73 million, a P/E ratio of -0.60 and a beta of -0.31. Longeveron has a 1-year low of $0.48 and a 1-year high of $1.80. The company’s fifty day moving average price is $0.94 and its 200-day moving average price is $0.72. The company has a debt-to-equity ratio of 0.05, a current ratio of 3.88 and a quick ratio of 3.88.

Longeveron (NASDAQ:LGVN) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.19) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.19). The firm had revenue of $0.40 million for the quarter, compared to analyst estimates of $0.33 million. Longeveron had a negative net margin of 1,844.49% and a negative return on equity of 202.41%.

Hedge Funds Weigh In On Longeveron

A hedge fund recently bought a new stake in Longeveron stock. XTX Topco Ltd acquired a new stake in shares of Longeveron Inc. (NASDAQ:LGVN) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 48,003 shares of the company’s stock, valued at approximately $62,000. XTX Topco Ltd owned approximately 0.32% of Longeveron as of its most recent SEC filing. Institutional investors and hedge funds own 10.01% of the company’s stock.

About Longeveron

Longeveron Inc is a clinical-stage biotechnology company focused on the development and commercialization of allogeneic cellular therapies designed to address aging-related and inflammatory conditions. The company’s primary therapeutic candidate, Lomecel-B, is an off-the-shelf mesenchymal stem cell product derived from bone marrow. Through its proprietary manufacturing process, Longeveron aims to produce a consistent, scalable cell therapy platform with potential applications in multiple disease areas.

Longeveron’s pipeline encompasses several ongoing and completed clinical studies.